ITUB20150390A1 - Metodo per la diagnosi di carcinoma endometriale - Google Patents
Metodo per la diagnosi di carcinoma endometriale Download PDFInfo
- Publication number
- ITUB20150390A1 ITUB20150390A1 ITUB2015A000390A ITUB20150390A ITUB20150390A1 IT UB20150390 A1 ITUB20150390 A1 IT UB20150390A1 IT UB2015A000390 A ITUB2015A000390 A IT UB2015A000390A IT UB20150390 A ITUB20150390 A IT UB20150390A IT UB20150390 A1 ITUB20150390 A1 IT UB20150390A1
- Authority
- IT
- Italy
- Prior art keywords
- analysis
- model
- classification
- sample
- metabolites
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 36
- 238000003745 diagnosis Methods 0.000 title claims description 12
- 201000009030 Carcinoma Diseases 0.000 title claims description 10
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 36
- 206010014733 Endometrial cancer Diseases 0.000 claims description 35
- 239000002207 metabolite Substances 0.000 claims description 25
- 238000013145 classification model Methods 0.000 claims description 23
- 238000004458 analytical method Methods 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 230000002503 metabolic effect Effects 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 15
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 13
- 238000012549 training Methods 0.000 claims description 12
- 238000003066 decision tree Methods 0.000 claims description 11
- 238000002705 metabolomic analysis Methods 0.000 claims description 11
- 238000000491 multivariate analysis Methods 0.000 claims description 10
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims description 9
- 238000001212 derivatisation Methods 0.000 claims description 8
- 230000014759 maintenance of location Effects 0.000 claims description 8
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 claims description 7
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 230000010354 integration Effects 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000013139 quantization Methods 0.000 claims description 5
- QRKUHYFDBWGLHJ-UHFFFAOYSA-N N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide Chemical compound FC(F)(F)C(=O)N(C)[Si](C)(C)C(C)(C)C QRKUHYFDBWGLHJ-UHFFFAOYSA-N 0.000 claims description 4
- MSPCIZMDDUQPGJ-UHFFFAOYSA-N N-methyl-N-(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)N(C)C(=O)C(F)(F)F MSPCIZMDDUQPGJ-UHFFFAOYSA-N 0.000 claims description 4
- XCOBLONWWXQEBS-KPKJPENVSA-N N,O-bis(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)O\C(C(F)(F)F)=N\[Si](C)(C)C XCOBLONWWXQEBS-KPKJPENVSA-N 0.000 claims description 3
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 238000012797 qualification Methods 0.000 claims description 3
- 238000011002 quantification Methods 0.000 claims description 3
- 238000004445 quantitative analysis Methods 0.000 claims description 3
- 238000002444 silanisation Methods 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- YKFRUJSEPGHZFJ-UHFFFAOYSA-N N-trimethylsilylimidazole Chemical compound C[Si](C)(C)N1C=CN=C1 YKFRUJSEPGHZFJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims 1
- 238000010239 partial least squares discriminant analysis Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 8
- 238000004817 gas chromatography Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
- 230000001431 metabolomic effect Effects 0.000 description 5
- 230000002357 endometrial effect Effects 0.000 description 4
- 238000009802 hysterectomy Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000012706 support-vector machine Methods 0.000 description 4
- 239000005051 trimethylchlorosilane Substances 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 238000002790 cross-validation Methods 0.000 description 3
- 239000001307 helium Substances 0.000 description 3
- 229910052734 helium Inorganic materials 0.000 description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000010801 machine learning Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000006828 endometrial hyperplasia Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010051909 Endometrial atrophy Diseases 0.000 description 1
- 208000005431 Endometrioid Carcinoma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 208000028730 endometrioid adenocarcinoma Diseases 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000007884 metabolite profiling Methods 0.000 description 1
- -1 methylsiloxane Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITUB2015A000390A ITUB20150390A1 (it) | 2015-02-27 | 2015-02-27 | Metodo per la diagnosi di carcinoma endometriale |
| PCT/EP2016/053726 WO2016135119A1 (en) | 2015-02-27 | 2016-02-23 | Method for the diagnosis of endometrial carcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITUB2015A000390A ITUB20150390A1 (it) | 2015-02-27 | 2015-02-27 | Metodo per la diagnosi di carcinoma endometriale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITUB20150390A1 true ITUB20150390A1 (it) | 2016-08-27 |
Family
ID=53284421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITUB2015A000390A ITUB20150390A1 (it) | 2015-02-27 | 2015-02-27 | Metodo per la diagnosi di carcinoma endometriale |
Country Status (2)
| Country | Link |
|---|---|
| IT (1) | ITUB20150390A1 (da) |
| WO (1) | WO2016135119A1 (da) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007057309A (ja) * | 2005-08-23 | 2007-03-08 | Yoshikimi Kikuchi | 子宮体癌の検出方法 |
| JP2007147459A (ja) * | 2005-11-28 | 2007-06-14 | Kazusa Dna Kenkyusho | 情報処理装置、プログラム、及びコンピュータ読み取り可能な記録媒体 |
| WO2011161186A1 (en) * | 2010-06-23 | 2011-12-29 | Biocrates Life Sciences Ag | Method for in vitro diagnosing sepsis utilizing biomarker composed of more than two different types of endogenous biomolecules |
-
2015
- 2015-02-27 IT ITUB2015A000390A patent/ITUB20150390A1/it unknown
-
2016
- 2016-02-23 WO PCT/EP2016/053726 patent/WO2016135119A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016135119A1 (en) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240019417A1 (en) | Methods and Systems for Determining Autism Spectrum Disorder Risk | |
| Enroth et al. | High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer | |
| Alberice et al. | Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography–mass spectrometry and capillary electrophoresis–mass spectrometry metabolomics approach | |
| Lavra et al. | Investigation of VOCs associated with different characteristics of breast cancer cells | |
| Szymańska et al. | Altered levels of nucleoside metabolite profiles in urogenital tract cancer measured by capillary electrophoresis | |
| JP2020515993A (ja) | 初期ステージの肺がん診断のための血漿ベースのタンパク質プロファイリング | |
| CN117368475A (zh) | 肺癌的检测和治疗方法 | |
| US8653006B2 (en) | Metabolite biomarkers for the detection of esophageal cancer using NMR | |
| Cheng et al. | Metabolomic biomarkers in cervicovaginal fluid for detecting endometrial cancer through nuclear magnetic resonance spectroscopy | |
| Yang et al. | High Ki-67 expression is a poor prognostic indicator of 5-year survival in patients with invasive breast cancer | |
| Wegdam et al. | A critical assessment of SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass | |
| JP6731957B2 (ja) | 子宮内膜癌の診断方法 | |
| Yuan et al. | Identification of diagnostic markers and lipid dysregulation in oesophageal squamous cell carcinoma through lipidomic analysis and machine learning | |
| CN112255335B (zh) | 用于区分良性和恶性卵巢肿瘤的血浆代谢标志物及其应用 | |
| Zhu et al. | Predicting Ki‐67 labeling index level in early‐stage lung adenocarcinomas manifesting as ground‐glass opacity nodules using intra‐nodular and peri‐nodular radiomic features | |
| Inagaki et al. | Comprehensive circulating microRNA profile as a supersensitive biomarker for early-stage lung cancer screening | |
| RU2697971C1 (ru) | Способ ранней диагностики рака легкого | |
| ITUB20150390A1 (it) | Metodo per la diagnosi di carcinoma endometriale | |
| CN107003371A (zh) | 用于确定主体患胰腺癌的可能性的方法 | |
| CN112255333B (zh) | 卵巢肿瘤尿液代谢标志物及其应用 | |
| JP2017516118A (ja) | 胎児奇形の早期検出のための非侵襲的診断法 | |
| Pyatnitskiy et al. | Identification of differential signs of squamous cell lung carcinoma by means of the mass spectrometry profiling of blood plasma | |
| Ye et al. | Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer | |
| Peña-Martín et al. | Identification of novel biomarkers for early diagnosis of malignant melanoma by untargeted LC-HRMS-based metabolomics: a pilot study | |
| Liu et al. | Uncovering nasopharyngeal carcinoma from chronic rhinosinusitis and healthy subjects using routine medical tests via machine learning |